Pro Medicus (ASX: PME) Share Price Pops On Phenomenal FY 2024 Results
The Pro Medicus (ASX: PME) share price gained more than 8% after it reported another set of strong results, beating analyst estimates.
Pro Medicus (ASX:PME)
Pro Medicus (ASX: PME) is a radiology software company founded in Melbourne in 1983 by friends and fellow wine connoisseurs Sam Hupert and Anthony Hall.
Pro Medicus (ASX: PME) was listed in 2000 during the tech bubble at a Pro Medicus IPO price of $1.15. The Pro Medicus share price was languishing until it acquired Visage Imaging from Mercury Computer Systems in 2009, selling just part of the acquired technology for a profit, not long after.
Visage Imaging has benefitted from ownership by Pro Medicus. Long serving General Manager of Visage Imaging, Malte Westerhoff lead the team of developers in Berlin, to develop Visage 7 viewer, which counts won the business of top notch US teaching hospitals like Mayo Clinic.
Minor Updates On 6 Stocks I Own
Albeit hardly thesis changing, there is some new information to consider regarding each of these stocks.
Pro Medicus (ASX: PME) Share Price Falls On Record H1 FY 2024 Results
The Pro Medicus (ASX: PME) share price dropped 13% after it reported another set of strong results, albeit with slower half-on-half growth.
Notes On The FY 2023 Pro Medicus (ASX: PME) Annual General Meeting
The FY 2023 Pro Medicus (ASX: PME) AGM further demonstrated the high quality of the business and the good nature of the leadership group.
Upcoming AGMs In November 2023
Here are some of the small-cap Annual General Meetings coming up this month.
Pro Medicus (ASX: PME) Shares Trade At All Time Highs After Record Contract Win
Why did the Pro Medicus share price spike to a record of $78.85 this morning and what is the relevant news for Pro Medicus (ASX: PME)?
Pro Medicus (ASX: PME) Share Price Rises On Record FY 2023 Results
The FY 2023 Pro Medicus Results showed record profits and a strengthening competitive advantage, with new products soon to be commercialised.
Pro Medicus CEO Sam Hupert Interview On Baby Giants Podcast
Claude, Matt and Andrew interview Pro Medicus CEO Sam Hupert.
Pro Medicus (ASX: PME) H1 FY 2023 Results Remain Strong
The H1 FY 2023 Pro Medicus (ASX: PME) Results showed record half year revenue and profit. While the outlook is rosy, cash flow was less ideal.
Pro Medicus (ASX: PME) AGM 2022 Emphasises Business Quality
The 2022 Pro Medicus AGM highlighted the strong competitive advantage of its key product, Visage.
My Top 6 Fluffy Dog Stocks With Target Buy Prices
When fear reigns it is hard to force yourself to buy growth stocks, but these are the half dozen I have most faith in (at the right price).
Pro Medicus (ASX: PME) Results Record Profit in FY 2022, Remains High Quality Business
Pro Medicus results show record revenue and profit in FY 2022. Is the Pro Medicus (ASX: PME) competitive advantage improving?
Fluffy Dog Watch List: Buy Price Targets For 6 More High Quality Stocks
I use watchlists with target desired buy prices to help me take advantage of market volatility in a calm and measured way.
Pro Medicus (ASX: PME) Customer List Is Impressive And Growing
A detailed look at the Pro Medicus major customer list, and why it needs both integrated delivery networks, and academic teaching hospitals.
Pro Medicus (ASX: PME) Remains Top Quality ASX Stock After H1 FY 2022 Result
My analysis of the Pro Medicus half year results suggest that the business is improving in quality as it grows.
My Target Buy Prices For High Quality Fluffy Dogs
Even though growth stocks are down considerably, in my view the top quality growth stocks are still up pretty overvalued.
Pro Medicus (ASX:PME) 2021 AGM Update
Pro Medicus (ASX:PME) revealed significant progress with its AI Accelerator at the PME 2021 AGM and a strong contract pipeline.
Talking Stocks: Damstra (ASX: DTC), Pro Medicus (ASX: PME), Tesla and Peloton on the Rask Invest Podcast
Owen Raszkiewicz, Anirban Mahanti, and Claude Walker sit down to chat Pro Medicus (ASX:PME), Damstra (ASX:DTC), Tesla and Peloton stocks.
Pro Medicus (ASX:PME) Reports Record Revenue And Profit In FY2021 Results
ASX superstar stock Pro Medicus (ASX:PME) has reported record results for FY2021, but how does the future look?
Potential Impacts On The Pro Medicus Share Price
The company seems in great shape but the market is starry-eyed.